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Abstract
Tumor cells grow in nutrient- and oxygen-deprived microenvironments and adapt to the suboptimal growth condi-
tions by altering their metabolic pathways. This adaptation process commonly results in a tumor phenotype that
displays a high rate of aerobic glycolysis and aggressive tumor characteristics. The glucose regulatory molecule,
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), is a bifunctional enzyme that is central to glycolytic
flux and is downstream of the metabolic stress sensor AMP-activated protein kinase (AMPK), which has been sug-
gested to modulate glycolysis and possibly activate isoforms of PFKFB, specifically PFKFB3 expressed in tumor
cells. Our results demonstrated that long-term low pH exposure induced AMPK activation, which resulted in the
up-regulation of PFKFB3 and an increase in its serine residue phosphorylation. Pharmacologic activation of AMPK
resulted in an increase in PFKFB3 as well as an increase in glucose consumption, whereas in contrast, inhibition of
AMPK resulted in the down-regulation of PFKFB3 and decreased glycolysis. PFKFB3 overexpression in DB-1 tumor
cells induced a high rate of glycolysis and inhibited oxygen consumption, confirming its role in controlling glycolytic
flux. These results show that low pH is a physiological stress that can promote a glycolytic phenotype commonly
associated with tumorigenesis. The implications are that the tumor microenviroment contributes to tumor growth
and treatment resistance.
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Introduction
Tumors experience dynamic microenvironmental changes that require
them to adapt to harsh nonphysiological conditions for continued
survival. Tumor cells adapt because their energy metabolism is altered
to survive mircoenvironmental changes, although the mechanisms of
these metabolic modifications are not well characterized. A hall-
mark characteristic of altered tumor metabolism is a shift toward
high-glucose flux or the Warburg effect, which is characterized by an
increase in aerobic glycolysis [1]. Tumor cells do not only display an
enhanced glycolytic rate but also exhibit roughly a 10-fold higher rate of
conversion of glucose into lactate compared with normal cells independent
of oxygen status. Glycolysis provides significantly less ATP in comparison
to oxidative phosphorylation. However, glycolytic ATP generation is
more than 100 times more rapid than oxidative phosphorylation, which
ultimately can sustain high proliferation rates of some tumors [2]. It has
been proposed that this energetically unfavorable environment is a stress
that may provide cells a selective advantage [3]. Normal cells surround-
ing the tumor may become nutrient starved and ultimately undergo
apoptosis, allowing the tumor more space to support growth [3]. The
high rates of glycolysis are positively correlated with the aggressive nature
of the tumor and demonstrate resistance to therapies [4].
The microenvironment of the tumor can be acidic, which is a direct
consequence of poor perfusion and the high rate of lactate production
[5]. The increase in glucose catabolism increases pyruvate accumulation
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where it is oxidized to enhance ATP production. Instead of being
shuttled into the mitochondria for oxidation, pyruvate is converted into
lactate, which cannot undergo mitochondrial oxidation and must be
extruded. This outward flux of lactate leads to a decreased extracellular
pH and creates an acidic environment where the metabolites cannot be
cleared due to poorly developed vasculature. As a result, the tumor cells
are chronically exposed to acidic conditions and develop a phenotype
that is associated with increased malignancy, increased rates of metasta-
sis, and chemotherapeutic resistance [6,7]. Tumor regulation of this
malignant survival pathway likely involves modulation of the expres-
sion and activity of key glycolytic enzymes. Therefore, understanding
the initiation of adaptation or the processes and pathways involved
could lead to the development of intervention or prevention methods.
One potential molecule that could act as a sensor and initiate
metabolic change is the ATP sensor AMP-activated protein kinase
(AMPK). AMPK functions as a cellular energy meter and its activity
increases when the ratio of AMP/ATP increases. In times of cellular
stress, AMPK signaling drives glycolytic flux in an effort to return to
energy homeostasis and replete cellular ATP levels through glucose
catabolism [8]. If a cell is under metabolic stress, AMPK works to
halt the anabolic processes that require ATP, such as protein synthe-
sis and cell proliferation. In addition, this protein works to increase
pathways that produce ATP, such as glycolysis [9]. Because of the
inefficient nature of the increased glycolytic phenotype seen in
cancer cells, there is a dysregulation of ATP production leading to
the activation of AMPK [10].
Downstream of AMPK is the glucose regulatory molecule,
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB).
PFKFB3 is a bifunctional enzyme with four tissue dependent isoforms
encoded by four genes (PFKFB1-4 ). The phosphofructo-2-kinase
(PFK) domain functions to promote glycolysis by increasing levels of
fructose-2,6-bisphosphate through phosphorylation of fructose-6-
phosphate and the fructose-2,6-biphosphatase domain functions to
catalyze the reverse reaction again producing fructose-6-phosphate
[11]. AMPK has been shown to activate an isoform of this bifunctional
enzyme, PFKFB2, through phosphorylation of serine 466 in heart
tissue after an acute ischemic event [12,13]. This is of particular inter-
est because of the mounting data indicating a role of the tumor PFKB
isoform PFKFB3 in adaptation to the hypoxic tumor environment.
This enzymatic stimulation of glycolysis leads to increased production
of both glycolytic ATP and lactate [14].
We propose that there is an AMPK-PFKFB3 interaction during
adaptation to low pH and that pathway is key in the up-regulation
of glycolysis resulting in the development of glycolytic and potentially
chemoresistant phenotypes, specifically the acidic pH tumor micro-
environment. We report a novel metabolic adaptation response
induced by low pH adaptation and describe mechanisms in vitro that
would predict tumorigenesis and treatment resistance as seen in clinical
settings. We describe the relationship between low pH and glycolytic
flux, which involves activation of AMPK and the up-regulation of
PFKFB3 leading to an increase in glucose consumption.
Materials and Methods
Cell Culture
Early-passage DB-1 melanoma cells, U87 glioblastoma cells, and
SK-MEL-5 melanoma cells were grown as monolayers at 37°C in
humidified 5% CO2 in α-minimum essential medium (fs) supple-
mented with 10% fetal bovine serum, 12 mM glucose, 10 ml/L non-
essential amino acids solution, and 2.9 g/L L-glutamine (α-MEM+).
Low pH medium was prepared at pH 6.7 as described [15]. Cells
were grown at pH 7.3 or in low pH conditions at pH 6.7. The
6.7 grown cells were adapted to growth at pH 6.7 for at least 14 days,
but no more than 60 days before they were used in experiments.
Immediate acidification was for 48 hours. Cell phenotypes after
adaptation to low pH have been described previously [15].
Transfections
Cells were transfected with a pcDNA3 5.4-kb vector (Invitrogen,
Carlsbad, CA) containing PFKFB3. PFKFB3 complementary DNA
(cDNA) was amplified using a forward primer (5′-CGGGATCC
ATGCCGTTGGAACTGACG-3′) and a reverse primer (5′-CCG
CTCGAGTCAGTGTTTCCTGGAGGAG-3′). In the forward
sequence, the BamHI domain is underlined, and in the reverse
sequence, the XhoI domain is underlined. The FLAG sequence, Asp-
Tyr-Lys-Asp-Asp-Asp-Asp-Lys, was used as the transfection marker.
AMPK Activation and Inhibition
To activate AMPK, DB-1 cells were treated with 10 mM met-
formin (Calbiochem, Darmstadt, Germany) for 72 hours. DB-1
melanoma cells and U87 glioblastoma cells were treated with 1 mM
AICAR (Sigma, St Louis, MO) for 8 hours to activate AMPK.
For AMPK inhibition, DB-1 cells were treated with Compound C
(Calbiochem) for 8 hours at 10 μM.
Rate of Glucose Consumption
A glucose detection kit (GHKB-2; Sigma), based on the enzymatic
conversion of glucose-6-phosphate and NAD+ to 6-phosphogluconate
and NADH, measured the amount of glucose present in the samples.
Cells were grown on T-25 culture flasks. When the cells were near con-
fluence, the medium was removed and replaced with new 7.3 α-MEM+
without 12 mM glucose or 6.7 α-MEM+. Enough 1-M glucose
solution was added to each flask to bring the final glucose concentration
to 20 mM. Exactly 6 or 24 hours later, 50-μl aliquots of medium were
removed from each flask. Subsequently, each aliquot was then stored in
an individual well of 96-well plate. The 96-well plate was then wrapped
with Parafilm (Thermo Fisher Scientific, Waltham, MA) and placed
in the freezer. To determine the rate of glucose consumption, the
samples were successively diluted: 1) 10 μl of thawed sample/90 μl
of deionized H2O and 2) 10 μl from a dilution of 1:100 μl glucose
assay reagent (G2020; Sigma). A 96-well plate spectrophotometer
was then used to determine the absorbance at 340 nm. A mean absor-
bance was calculated based on the individual absorbance readings
from each of the aliquots removed.
Total glucose consumption after AMPK inhibition with Com-
pound C (Sigma) and AMPK activation by AICAR (Sigma) was
measured using an ACCU-CHECK glucometer. Normal pH U87
cells and chronically acidified DB-1 cells were cultured in six-well
plates and treated with Compound C or AICAR, respectively.
Medium samples were taken in 1-ml aliquots before and after
Compound C and AICAR treatment and were stored at −20°C until
analyzed. Samples were thawed at 37°C and read three times each.
Lactate Production
A lactate detection kit (826-UV; Sigma) based on the enzymatic
conversion of lactate and NAD+ to pyruvate and NADH was used to
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measure the amount of lactate present in the samples. To determine
the rate of lactate production, NAD (826-3; Sigma) was reconsti-
tuted as directed in the protocol (826-UV; Sigma). A 10:100 dilu-
tion of sample (obtained from the glucose consumption assay 96-well
plate)/NAD solution was prepared, and the absorbance at 340 nm
was measured using a 96-well plate spectrophotometer. A mean
absorbance was calculated from the individual absorbance readings
from each of the aliquots removed.
Western Blot Analysis
Western blot analysis was carried out with a total of 25 μg of each
sample in 7% and NUPAGE gels (Invitrogen). Protein determina-
tion was done using the Protein dotMETRIC Assay (G-Biosciences,
Maryland Heights, MO). Antibodies to p-AMPK Thr 172, total
AMPK (Abcam, Cambridge, MA), phosphorylated p53 Ser 392,
total p53 (Cell Signaling Technology, Boston, MA), and PFKFB3
(Abnova, Taipei, Taiwan) were used at a dilution of 1:1000. The
phosphorylated serine antibody was used at a dilution of 2 μg/ml
(Abcam), and an antirabbit secondary was used at a dilution of
1:10000 was used for all Western blot analyses. Western detection
was carried out using CDP star from Tropix (Applied Biosystems,
Chicago, IL). PFKFB3 overexpression was determined by Western
blot using anti-FLAG antibody (Sigma Aldrich).
Immunoprecipitations
Chronically acidified and pH 7.3 SK-MEL-5 cells grown in cul-
ture were washed twice with ice-cold PBS and then were lysed with
ice-cold NP-40 buffer substituted with 1% Triton X, 150 mM
NaCl, and 50 mM Tris-HCl. Protease inhibitor cocktail, NaF,
and NaV were added immediately before use. Lysates were immuno-
precipitated with 10 μl of anti-PFKFB3 (Abnova) antibody over-
night at 4°C with gentle agitation. Before adding to lysates, 75 μl
of Protein A Magnetic Beads (Abnova) was washed twice with cold
immunoprecipitation (IP) buffer. Lysates were then added to beads
and incubated overnight at 4°C on a rocking platform. Beads were
then pelleted by centrifugation and washed three times with buffer.
Lithium dodecyl sulfate (LDS) sample buffer was then added to beads,
samples were boiled for 10 minutes at 100°C, and the supernatant
was removed.
Oxygen Consumption
The rate of oxygen consumption was measured at 37°C using a
Clark electrode and amplifier (Yellow Springs Instrument Co, Yellow
Springs, OH) as previously described [15]. A water bath was used to
maintain a constant temperature, and cells were stirred continuously.
MLA Brand pipettes (Fisher) were used to add cells and solutions to the
measurement chamber. MLA Brand pipettes were chosen because of
their inability to expel excess air into the chamber by overdepressing
the plunger. For each experimental trial, 30 μl of cell suspension was
placed in the oxygen consumption chamber, and a basal rate of oxygen
consumption was measured for 5 minutes before addition of 5 μl of
either HEPES respiration buffer [15], 16.7 mM glucose, or 100 μM
dinitrophenol (DNP). The addition of DNP allows for the measure-
ment of maximum oxygen consumption because DNP uncouples
oxidative phosphorylation, leading to oxygen consumption without
ATP production. (The basal rate is defined as the rate of oxygen con-
sumption of cells in buffer before an addition of another solution.) The
rate of oxygen consumption was then measured for another 5 minutes
after addition of an agent. A 100-μl aliquot of the cell solution was
removed from the chamber after the second interval and stored at
−20°C before protein determination.
ATP Assay
Intracellular ATP concentrations were assayed using a colorimetric
ATP assay kit (ab83355; Abcam). Normal and chronically acidified
DB-1 and SK-MEL-5 cells were lysed according to the manufac-
turer’s instructions. Briefly, 1 × 106 cells were lysed in 100 μl of pro-
vided assay buffer. Samples were run through a 10-kDa filter (Abcam)
to remove any interfering proteins before analysis. Samples were placed
into a 96-well plate, and the reaction mixture was made according to
the protocol provided by the manufacturer and read at 550 nm.
Statistical Analysis
All measurements represent the mean of three different experiments
with three values of each ±SE or SD where indicated. Statistical signif-
icance was evaluated using a Student’s t test, and significant values were
noted as follows: *P < .05, **P < .01 to .001, and ***P < .001.
Results
Short-term and Long-term Acidification Activates AMPK
and PFKFB3
AMPK acts as a cellular fuel gauge and responds to changes in
energy status by increasing glucose usage and by decreasing anabolic
processes. Once activated, AMPK induces a series of downstream
glycolytic events aimed at increasing energy production. Therefore,
we investigated whether AMPK could act as a metabolic sensor dur-
ing short-term and long-term acidification and increase the expres-
sion and activation of glycolytic proteins, a hallmark of tumors.
After both short-term and long-term acidification of DB-1 cells,
activation of AMPK was observed as measured by phosphorylation
of the alpha subunit at Thr 172 (Figure 1, A and B). AMPK activa-
tion was also confirmed in chronically acidified U87 cells (Figure 1,
C and D). AMPK activation has been shown to inhibit proliferative
processes through the inhibition of the mammalian target of rapamycin
pathway. The protein levels of p-mTOR were decreased after low pH
adaptation and confirm AMPK activity (Figure 1, E and F ).
To explore a possible mechanism of AMPK activation by low pH, we
assayed intracellular ATP concentrations in normal and chronically acid-
ified low-pHDB-1 cells and observed that the low-pH cells had roughly
two-fold less ATP compared with normal-pH cells (Figure 1G ). The
decrease in ATP concentration after acidification was confirmed in
SK-MEL-5 cells (Figure 1H). The decreased ATP levels after adaptation
to low pH are indicative of low energy levels, which could contribute to
the activation of AMPK after long-term acidification.
Because AMPK can increase and activate glycolytic enzymes, we
investigated the effect of acidification on the level of PFKFB3, a
major glucose regulatory protein central to glyolytic metabolism. After
acutely acidifying DB-1 cells to pH 6.7 for 48 hours and chronically
(>14 days), we observed an increase in protein levels of PFKFB3
(Figure 2, A and B) and confirmed this increase further in chronically
acidified U87 glioblastoma cells (Figure 2, C and D).
Previous data demonstrated that when AMPK was activated because
of an ischemic event in heart tissue, there was a subsequent phosphor-
ylation of a serine residue on the heart PFKFB isoform PFKFB2, pro-
moting an oxygen-sparing means of energy production [16]. PFKFB3
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is a bifunctional enzyme with both a kinase component and a phospha-
tase component, which are regulated posttranslationally. The kinase
portion of PFKFB3 becomes phosphorylated at Ser 461 and in turn
increases glycolysis [17]. We hypothesized that, after adaptation of tu-
mor cells, in addition to an increase in protein levels, there would also
be a phosphorylation event on PFKFB3, enhancing its kinase activity,
thus promoting glycolysis. Owing to the lack of a commercially avail-
able antiphosphorylated PFKFB3 at Ser 461, we used a pan antiserine
antibody to detect changes in PFKFB3 phosphorylation on serine resi-
dues followed by long-term acidification. We immunoprecipitated
Figure 1. Protein levels of phosphorylated AMPK in acutely and chronically acidified DB-1 and U87 cells and intracellular ATP levels in
chronically acidified SK-MEL-5 cells. (A) Western blot of p-AMPK and total AMPK in acutely and chronically acidified DB-1 melanoma cells
and (B) protein quantification. (C) Protein levels of chronically acidified U87 glioblastoma cells and (D) protein quantification. (E) Western
blot of p-mTOR and total mTOR in chronically adapted U87 cells and (F) protein quantification. Relative fold change in ATP levels after
long-term adaptation in (G) DB-1 and (H) SK-MEL-5 cells. Blots and ATP assay are representative of at least three independent experi-
ments. Bars are mean ± SE. ***P < .001 when compared with control.
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PFKFB3 from normal and chronically adapted SK-MEL-5 melanoma
cells and then analyzed phosphorylation levels using Western blot. We
observed a marked increase in total serine phosphorylation after adap-
tation to low pH compared with cells grown at normal pH (Figure 2, E
and F ).
Manipulation of AMPK Activation Modulates PFKFB3 Activity
and Alters Glucose Consumption
To confirm that AMPK is the upstream sensor that regulates gly-
colytic flux in our low-pH model, we inhibited AMPK with the ATP
competitive inhibitor Compound C in chronically acidified U87
glioblastoma cells. After 24 hours of treatment with Compound C,
we observed a decrease in AMPK phosphorylation and a subsequent
decrease in PFKFB3 protein levels (Figure 3, A and B). A functional
decrease in glucose consumption was also observed in chronically
adapted U87 cells after treatment with Compound C (Figure 3C ).
To demonstrate that AMPK could induce the low-pH–adapted
phenotype, we pharmacologically activated AMPK using the anti-
diabetic drug metformin and the more specific activator AICAR in
normal-pH DB-1 and U87 cells. After treatment with metformin for
72 hours (Figure 3, D and E ) or AICAR for 8 hours (Figure 3, F and
G ), we observed phosphorylation of AMPK as well as an increase in
PFKFB3 protein levels. Again, we assayed glucose consumption after
activation of AMPK with AICAR and found that activation of
AMPK in normal pH cells recapitulated the low-pH phenotype
and caused an increase in glucose consumption (Figure 3H ).
To demonstrate that PFKFB3 alone could induce the observed
changes in glucose flux, we transfected DB-1 melanoma cells with
the PFKFB3 gene. After overexpression, there was an increase in
Figure 2. Protein levels of PFKFB3 and phosphorylated serine residues after short-term and long-term acidification of DB-1, U87, and
SK-MEL-5 cells. (A) Western blot of PFKFB3 protein levels in acutely and chronically acidified DB-1 cells and (B) protein quantification.
(C) Protein levels of PFKFB3 in chronically acidified U87 cells and (D) protein quantification. Immunoprecipitation of PFKFB3 in chron-
ically adapted low-pH SK-MEL-5 cells and (E) Western blot of PFKFB3 and pan serine phosphorylation and (F) protein quantification.
Blots are representative of at least three independent experiments.
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glucose consumption and lactate production (Figure 4, A-C ) relative
to vector controls. However, the basal rates of oxygen consumption
of the PFKFB3 overexpression after the addition of glucose were the
same compared with the vector (Figure 4D). Therefore, we deter-
mined the maximum rate of respiration in these cells using 100 μM
DNP, which inhibits ATP production by uncoupling oxidative phos-
phorylation, leading to increased oxygen consumption. The PFKFB3
overexpressors had a lower maximum rate of respiration than the vec-
tor; this confirms a shift from oxidative respiration to glycolysis. Taken
together, these results indicate that a low-pHmicroenvironment results
Figure 3.Manipulation of AMPK decreases PFKFB3 expression and glycolysis. (A) Western blot of p-AMPK, total AMPK, and PFKFB3; (B)
protein quantification in chronically acidified U87 cells; and (C) rate of glycolysis in U87 after 8 hours of treatment with Compound C
expressed in a relative fold decrease. (D) Western blot of p-AMPK, total AMPK, and PFKFB3 and (E) protein quantification after 72 hours
of treatment with Metformin. (F) Western blot of p-AMPK, total AMPK, and PFKFB3; (G) protein quantification; and (H) rate of glucose
consumption after AMPK activation with 1 mM AICAR in pH 7.3. U87 cells were expressed as a relative fold increase. Bars are
mean ± SE. ***P < .001 when compared with control. Experiments in this figure were repeated twice.
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in AMPK-mediated changes in glycolytic flux and PFKFB3 is a down-
stream mediator of the changes.
Discussion
We show here that extracellular pH has a direct affect on glycolytic
flux in our tumor model. Exposure to low extracellular pH induced
phosphorylation of AMPK and increased glucose uptake in chroni-
cally acidified cells. The glycolytic effect was recapitulated through
the overexpression of PFKFB3. We also demonstrate a shift from
oxidative metabolism to glycolysis by the overexpression of PFKFB3,
which is consistent with a highly glycolytic phenotype that could
provide a survival advantage in a low-oxygen tension environment.
However, we also demonstrated that low-pH adaptation itself leads
to a decrease in intracellular ATP concentrations so it is possible that
decreased energy levels can contribute to low-pH–induced activation
of AMPK, and this indicates that low pH itself may propagate the
glycolytic and aggressive phenotype of tumors.
Induction of AMPK resulted in an increase in glycolytic activity
despite an oxygen-rich environment, which indicates that low-pH
adaption can induce the Warburg effect. Therefore, it is possible that
low pH induces an oxygen-sparing phenotype, which would be
advantageous in a hypoxic tumor setting. Tumor cells that exhibit
metabolic reprogramming have demonstrated survival advantages,
increased metastasis, and chemoresistance [18]. Overexpression of
PFKFB3 was sufficient to induce the shift in glycolytic rate and
was induced downstream of AMPK after low pH adaptation; this
is in addition to the two-fold reduction in ATP concentration in
chronically acidified cells compared with normal-pH cells. This
observation provides a reasonable mechanism suggesting that tumors
sense environmental changes and have the ability to quickly adapt.
Furthermore, it indicates that the mechanism of adaptation involves
the activation of PFKFB3.
Another advantage of high glycolytic rates in tumors is the potential
to increase pentose cycle activity. High glycolytic flux results in the
reduction of NAD+ to NADH. The depletion of NAD+ is rectified
through the oxidation of NADH to NAD+ in the conversion of
pyruvate to lactate, allowing glycolysis to persist. Increases in both
glycolysis and the pentose cycle are believed to play a role in circum-
venting toxicity from high levels of oxidative stress that result from
low glucose levels [19]. We have shown here that we can reduce
the glycolytic rate with compounds such as the AMPK inhibitor
Compound C. Targeting AMPK could provide a strategy to counter
the protective effects of glycolysis and sensitize tumors to therapy not
only by decreasing the reducing power of cells but also because block-
ing glycolysis is believed to cause an accumulation of pernicious
hydroperoxide radicals [20].
In addition to targeting AMPK, the glycolytic enzyme PFKFB3
may provide a more direct target. There is evidence that tumor cells
are more resistant to glucose deprivation than nontransformed cells.
This paradigm sets the stage for the development of 2-deoxy-D-glucose,
which competes with glucose for uptake by chemically inducing a state
of glucose deprivation [20]. Inhibition of PFKFB3 has also come to the
forefront as an important potential therapeutic target because of its very
high kinase activity. This markedly high kinase activity is hypothesized
to have a sizeable role in driving the glycolytic phenotype seen in cancer
Figure 4. Effect of PFKFB3 expression on glycolysis and oxygen consumption. Characterization of PFKFB3 overexpression in DB-1 cells
grown at pH 7.3 by anti-FLAG detection by (A) Western blot, and (B) its effect on the rate of glucose consumption, (C) on lactate pro-
duction, and (D) on oxygen consumption with and without DNP. Glucose and lactose are expressed as a relative fold difference to vector
at 6 and 24 hours. Clark electrode oxygen consumption readings are representative, and numbers indicate the relative rate after addition
(posttreatment rate / pretreatment rate). Bars are mean ± SE of three independent experiments. **P < .01 to .001, ***P < .001 when
compared with control.
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cells [21]. This glycolytic targeting could be highly feasible given the
frequency of tumor acidosis, independent of tumor oxygen tensions.
Many studies have focused on the use of AMPK as an antitumor
therapy, and there has been promising chemoprevention results using
the antidiabetic drug metformin to activate AMPK and mimic a
cellular starvation state [22]. There is also a potential antitumor role
of AMPK activation through p53 signaling or mTOR inhibition
[23,24], and connections between AMPK and p53 have been char-
acterized where activation of AMPK leads to activation of the tumor
suppressor p53 and p53 target genes [25]. However, we have previ-
ously shown that, in DB-1, the induction of p53 may be protumori-
genic because of the induction of downstream p53 antagonists by
p53 itself [26]. Metformin is also used to stimulate glucose uptake
[27], and the results presented here indicate that activation of AMPK
could potentially be advantageous to already established tumors, pos-
sibly through enhancing the glycolytic flux.
There is also a potential role of mTOR in regulating autophagy.
Autophagy is the cellular process of recycling cytoplasmic compo-
nents when components are damaged or in excess, using lysosomal
machinery. This process of recycling becomes important in starvation
states, such as mediated by AMPK, to synthesize important proteins
or break down cellular components to use as catabolic fuel. We also
observed a decrease in mTOR phosphorylation, which could play a
major role in tumor resistance to environmental and treatment stress
by induction of autophagy. Low pH could also play a more direct
role in mTOR regulation. Balgi et al. [28] demonstrated that mTOR
is sensitive to pH changes and is inhibited in a low-pH environment.
The group hypothesized that this down-regulation of mTOR signal-
ing may aid in adaptation to an energetically unfavorable micro-
environment. Both AMPK-mediated and direct down-regulation of
mTOR by pH would support an autophagic process [29,30]. Future
studies will explore the effect of pH on mTOR, which is involved in
autophagy and possibly chemoresistance. However, in the interim,
antitumor therapies focused on the use of AMPK should consider
its potentially undesirable ability to induce a PFKFB3 and promote
a glycolytic state.
Elucidation of mechanisms involved with low pH adaptation
has important therapeutic implications. Tumors exhibiting an acidic
extracellular pH are not suited to be treated with weak base chemo-
therapeutics, and pH must be taken into consideration in treatment
protocols. Immediate tumor alkalinization with systemic adminis-
tration of sodium bicarbonate has sensitized mammary tumors to
doxorubicin and mitoxantrone in vivo [31,32]. The use of proton
pump inhibitors to decrease cellular acid extrusion has also shown
promise in vivo to sensitize tumors to weak base chemotherapy
[33]. Conversely, exploiting the acidic extracellular pH by pairing
a low-pH phenotype with a weak acid drug, such as melphalan
can circumvent drug resistance conferred by low pH and has been
successful in melanoma xenograft models [34]. Understanding tumor
pH and the metabolic adaptations involved can help to adapt treat-
ment protocols and improve therapeutic outcomes.
In conclusion, we show here for the first time that low pH is a
principal factor in the paradigm of tumor metabolism and can be
involved in the genesis of the glycolytic phenotype as well as contrib-
ute to the further deterioration of metabolic regulation. AMPK
can potentially serve as a switch to induce PFKFB3, in which over-
expression was sufficient to increase glucose consumption and
induce an oxygen-sparing phenotype. The modulation of AMPK
and the subsequent effect on tumor metabolism is an important
approach to understanding low-pH–induced glycolytic signaling
centering around PFKFB3.
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